U-VUE Biomarker Datasheet - pan-CK

Sharon Kedar

Sharon is Co-Founder, Partner of Northpond Ventures. Sharon is currently a board director at 908 Devices, Emulate, Isoplexis, Ultivue, and Vizgen. She was previously CFO of Sands Capital Management. Over her 15 years with Sands Capital, assets under management grew from $1.5 billion to $50 billion. Prior to Sands Capital, Sharon was a consultant at McKinsey & Company. Sharon has an MBA from Harvard Business School and a BA in Economics from Rice University. She is a CFA charterholder. Sharon is an advocate for financial literacy and her work has been featured nationally, including her two books, ON MY OWN TWO FEET: A Modern Girl’s Guide to Personal Finance and GET FINANCIALLY NAKED: How to Talk Money with your Honey.

Jacques Corriveau

President and CEO

Philippe Mourere

Sr. Vice President of Commercial Operations

Philippe came to Ultivue after serving as Vice President of Global Sales and Marketing at Cell Signaling Technology and as Senior Director, Corporate Development, for the Life Science & Technology Business Unit at PerkinElmer. Previously, he served as Senior Director, Global Sales & Marketing, Discovery, Alliances & Services and as Marketing Manager at Caliper Life Sciences, which was acquired by PerkinElmer for approximately $600 million. Earlier in his career, Philippe served as Sales Manager at CIS Bio International, prior to its acquisition by Ion Beam Applications, S.A. Philippe received his MS in Molecular and Cell Biology from the University Paul Sabatier and his D.E.S.S. in Biology and Biotechnology from St. Jerome University, France.

Sean Downing

Director of Biology & Biomarker Programs

Throughout his career, Sean has implemented pathology workflows at several companies in work spanning both proteomics and genomics. Prior to Ultivue, he established and ran PerkinElmer’s Contract Research Organization laboratory offering a menu of TSA-based staining services. Previously, Sean was one of the principal inventors of the first to market, pan-cancer NGS test at Foundation Medicine. Earlier in his career, he was a post-doc and junior faculty member at Harvard Medical School with appointments at Dana-Farber Cancer Institute and Boston Children’s Hospital, respectively. Sean has a Ph.D in Cancer Genetics from the University of New South Wales, an MS in Molecular and Cellular Biology from the University of Massachusetts Amherst, and a BS in Biotechnology from Rochester Institute of Technology. He is currently pursuing an MBA to further his ability to serve clients.

Louis Levy

Director of Corporate and Business Development

Prior to Ultivue, Louis was with Cepton, a strategy consulting boutique for French mid-size biotechs, where he worked on pharmaceutical development, European commercial launches, and R&D organizations. He was involved in notable licensing transactions in allergy immunotherapy (Stallergenes-Shionogi) and hemophilia (Ipsen-Inspiration Biopharm). Earlier, as a Harvard Blavatnik Fellow, he investigated biotech entrepreneurship trends in NYC and worked on commercialization of the Harvard technology that initially led to the launch of Ultivue. Louis has a MS degree in engineering from the French grande école Telecom Bretagne, and a MBA from Harvard Business School.

Mack Schermer

Executive Director of Product Development

Mack has been leading product development teams and projects in the life science space for many years. Prior to Ultivue he was an R&D Director for PerkinElmer Diagnostics, leading the development of In Vitro Diagnostics assay kits marketed around the world for newborn screening and prenatal diagnosis. While at PerkinElmer he transitioned his R&D group from developing research products to working under an ISO1385 and QSR compliant quality system. Previously, Mack led a multidisciplinary engineering team at Packard Bioscience to architect and develop a suite of instruments and software for producing and analyzing microarrays. Mack holds a degree in mechanical engineering from MIT and is an inventor on 22 U.S. Patents.

Mark Bobrow

Executive Director of Research

Mark has been an innovative assay developer and R&D leader for many years. Prior to Ultivue, Mark was the scientific reviewer for and technical advisor to all of the assay projects in PerkinElmer’s Diagnostics division, spanning three continents. Mark held a succession of positions in R&D leadership with PerkinElmer, where he invented the now prolifically-used Tyramide Signal Amplification (TSA) technology and led the development of a family of fluorescent cyanine dyes used in a broad range of assays. Mark started his career at DuPont Diagnostics and NEN Life Sciences (joining PerkinElmer when it acquired NEN). Mark holds a Ph.D. degree in biochemistry from The Graduate Center, City University of New York, a BS in chemistry from Brooklyn College, and is an inventor on 27 U.S. Patents.

Michele Giovenelli

VP of Finance and Operations

Michele is an experienced, operationally oriented finance executive with over 25 years of experience in accounting and finance in the biotechnology industry. Experience with pre-clinical, clinical and commercial stage companies. Prior to joining Ultivue, Michele served as the Senior Director of Finance at Kala Pharmaceuticals. Prior to joining Kala Pharmaceuticals, she acted as an independent financial consultant and prior to that held senior finance positions at SynapDx, and BG Medicine. Earlier in her career, Michele held a variety of finance and accounting positions at Charles River Laboratories. Michele graduated from Salem State University with a BS in Accounting.

Martin Madaus

Executive Chairman of the Board

Martin brings more than 20 years of experience in the diagnostics and life science industries. He most recently served as President, Chairman and CEO of Millipore Corporation, recently acquired by Merck KGaA. Before joining Millipore, Dr. Madaus was President, CEO and head of North American Operations for Roche Diagnostics Corporation. Prior to this he served as Vice President of Business Development for Roche Molecular Diagnostics and General Manager of Boehringer Mannheim Canada. He also held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corporation in both Germany and the US. Martin is a director of the Massachusetts High Technology Council and serves on the Life Sciences Collaborative Leadership Council of the Massachusetts Technology Collaborative. He holds a Doctor of Veterinary Medicine from the University of Munich, Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover, Germany.

Martin Madaus

Martin brings more than 20 years of experience in the diagnostics and life science industries. He most recently served as President, Chairman and CEO of Millipore Corporation, recently acquired by Merck KGaA. Before joining Millipore, Dr. Madaus was President, CEO and head of North American Operations for Roche Diagnostics Corporation. Prior to this he served as Vice President of Business Development for Roche Molecular Diagnostics and General Manager of Boehringer Mannheim Canada. He also held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corporation in both Germany and the US. Martin is a director of the Massachusetts High Technology Council and serves on the Life Sciences Collaborative Leadership Council of the Massachusetts Technology Collaborative. He holds a Doctor of Veterinary Medicine from the University of Munich, Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover, Germany.

Daguang Wang

Daguang is the managing director of Yonjin Capital, the North America and Europe investment arm of Yongjin Group in Shanghai, China. Before venture investment, Daguang spent more than 20 years in the biotech and pharmaceutical industry with Amgen, Memory Pharmaceuticals, PsychoGenics, EMD Serono and Sanofi. Daguang started his career as a scientist in neuroscience, working in the areas of neurodegenerative diseases and psychiatric disorders, before moving to business development and external innovation with a focus on neuroscience, multiple sclerosis and rare diseases. Daguang was a global lead of business development and external innovation for neuroscience at Sanofi before joining Yonjin Capital in 2018. Daguang serves on the board of multiple biotech companies.
Daguang received his bachelor degree in biochemistry from Jilin University in China, and his PhD in molecular genetics from the Washington University in St Louis in the US. Daguang conducted postdoctoral research at Stanford University with Professor Roger Kornberg.

Andrew L. Stevenson

Andy has been serving as Chief Investment Officer at Loreda for 6 years. In this role he helps manage a diverse pool of both personal and charitable assets for a single family. Overall the portfolio consists of private and public investments made both on a direct basis and with select managers. In addition to his role at Loreda, Andy is a general partner, managing a similar pool of assets for his own family. Prior to managing the investments on a full time basis, he served in a variety of roles for a public financial services firm, including forecasting and planning, as well as Investor relations. He began his career as a consultant and after business school, spent two years at Bain & Company in their Boston office. Andy graduated from Phi Beta Kappa from Bowdoin College and has an MBA from Harvard Business School.

Kevin Heyeck

Kevin Heyeck is a Venture Partner at 6 Dimensions Capital, a leading China and U.S. focused investment group specializing in healthcare and life sciences formed out of the merger between Frontline Bioventures and WuXi Healthcare Ventures. Kevin is a seasoned biopharmaceutical executive with 20 years of experience building multiple venture-backed life sciences companies, with an extensive worldwide deal sheet. He received his B.A. in Politics at the University of California, Santa Cruz.

Keith Crandell

Keith is a co-founder and Managing Director of ARCH Venture Partners, where he focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. Keith has played a key role in the formation and initial funding round of countless ARCH-backed companies. Prior to the founding of ARCH, Keith was with the specialty chemical and polymer company, Hercules, Inc. He holds an MBA from The University of Chicago, an MS in Chemistry from the University of Texas at Arlington, and a BS in Chemistry and Mathematics from St. Lawrence University.

Peng Yin

Peng is a Professor in the Department of Systems Biology at Harvard Medical School. He also serves as a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he co-founded Ultivue. Previously, he was a senior postdoctoral scholar in bioengineering and computer science at Caltech's Center for Biological Circuit Design. Peng obtained his Ph.D. degree in computer science and MS in molecular cancer biology from Duke University, and a BS in biochemistry and molecular biology from Peking University.

David Walt

David is a faculty member at Harvard Medical School in the Department of Pathology at Brigham and Women’s Hospital, a Member of the Wyss Institute and a Howard Hughes Medical Institute Professor. Previously, he was a University Professor at Tufts University. Before co-founding Ultivue, David was the Scientific Founder of Illumina Inc., and Quanterix Corp. He did postdoctoral studies at MIT after earning a Ph.D. in chemical biology from SUNY at Stony Brook and a BS in chemistry from the University of Michigan.

Michael J. Natan

Prior to joining Ultivue, Michael was an Executive Director, New Business Development for Cabot Corporation. He joined Cabot when it acquired Oxonica Materials Inc., for which Michael served as CEO. Prior to Oxonica, Michael was a co-founder and CEO of Nanoplex Technologies Inc. (acquired by Oxonica), and served as CTO and then as VP, Business Development for SurroMed. Michael started his professional career as an Assistant Professor, Associate Professor, and Professor of Chemistry at Penn State University. His education comprised postdoctoral research at Northwestern University, a Ph.D. in Chemistry from MIT, and a degree in Chemistry with Honors from Yale University.